Ipsen SA (IPN):企業の財務・戦略的SWOT分析

◆英語タイトル:Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1638
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,125見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,375見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ipsen SA (IPN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ipsen SA (Ipsen) is a global specialty biopharmaceutical company that manufactures and distributes drugs for the treatment of cancer and rare and neurological diseases. The company develops and commercializes novel medicines in cancer, neuroscience and rare diseases. It also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatology diseases. Ipsen sells its drugs through distributors and directly to hospitals in few countries. It has research and development (R&D) facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

Ipsen SA Key Recent Developments

Apr 22,2020 Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact
Apr 01,2020 Ipsen donates two million euros to the Institut Pasteur to support research on COVID-19
Feb 13,2020 Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook
Jan 14,2020 Ipsen appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ipsen SA – Key Facts
Ipsen SA – Key Employees
Ipsen SA – Key Employee Biographies
Ipsen SA – Major Products and Services
Ipsen SA – History
Ipsen SA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Ipsen SA – Business Description
Business Segment: Consumer Healthcare
Overview
Performance
Business Segment: Specialty Care
Overview
Performance
Geographical Segment: Major Western European Countries
Target Markets
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other European Countries
Target Markets
Performance
Geographical Segment: Rest of the World
Target Markets
Performance
R&D Overview
Ipsen SA – Corporate Strategy
Ipsen SA – SWOT Analysis
SWOT Analysis – Overview
Ipsen SA – Strengths
Ipsen SA – Weaknesses
Ipsen SA – Opportunities
Ipsen SA – Threats
Ipsen SA – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ipsen SA, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 22, 2020: Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact
Apr 01, 2020: Ipsen donates two million euros to the Institut Pasteur to support research on COVID-19
Feb 13, 2020: Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook
Jan 14, 2020: Ipsen appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer
Dec 18, 2019: Ipsen announces departure of David Meek as chief executive officer
Nov 05, 2019: Ipsen appoints Howard Mayer, M.D. as Executive Vice President and head of Research and Development
Oct 23, 2019: Ipsen delivers strong double-digit sales growth for the third quarter of 2019 and confirms full year 2019 guidance
Oct 16, 2019: Ipsen gains licence to Blueprint Medicines’ FOP drug candidate
Jul 25, 2019: Ipsen delivers strong results for the first half of 2019 with robust double-digit sales growth and improved Core Operating margin and upgrades its guidance for full year 2019
May 14, 2019: Ipsen to host an Investor Day to highlight its innovative R&D pipeline and provide financial outlook for 2022
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ipsen SA, Key Facts
Ipsen SA, Key Employees
Ipsen SA, Key Employee Biographies
Ipsen SA, Major Products and Services
Ipsen SA, History
Ipsen SA, Subsidiaries
Ipsen SA, Joint Venture
Ipsen SA, Key Competitors
Ipsen SA, Ratios based on current share price
Ipsen SA, Annual Ratios
Ipsen SA, Annual Ratios (Cont...1)
Ipsen SA, Annual Ratios (Cont...2)
Ipsen SA, Interim Ratios
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Ipsen SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Ipsen SA, Performance Chart (2015 - 2019)
Ipsen SA, Ratio Charts
Ipsen SA, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Ipsen SA, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[Ipsen SA (IPN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nikkei Inc.:企業の戦略的SWOT分析
    Nikkei Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Centerra Gold Inc.:企業の戦略・SWOT・財務分析
    Centerra Gold Inc. - Strategy, SWOT and Corporate Finance Report Summary Centerra Gold Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Battelle Memorial Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Battelle Memorial Institute (Battelle) is a nonprofit research and development (R&D) organization. It carries out discovery, design, development, and manufacture of products, and renders its services to government and commercial customers. The institute manages national laboratories and main …
  • Valvoline Inc (VVV):企業の財務・戦略的SWOT分析
    Valvoline Inc (VVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Amicus Therapeutics Inc (FOLD):企業の財務・戦略的SWOT分析
    Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Advocate Aurora Health Care:企業の戦略的SWOT分析
    Advocate Aurora Health Care - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Securitas AB:戦略・SWOT・企業財務分析
    Securitas AB - Strategy, SWOT and Corporate Finance Report Summary Securitas AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Bc Hydro
    Bc Hydro - Strategy, SWOT and Corporate Finance Report Summary Bc Hydro - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Blueknight Energy Partners LP:企業のM&A・事業提携・投資動向
    Blueknight Energy Partners LP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Blueknight Energy Partners LP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • BioView Ltd (BIOV):医療機器:M&Aディール及び事業提携情報
    Summary BioView Ltd (BioView) develops, manufactures and markets automated cell imaging and analysis solutions, which incorporate proprietary imaging, analysis and review technology. The technology provides automatic control of fully motorized fluorescent and bright-field microscopes fitted with hig …
  • RSWM Ltd. (RSWM):企業の財務・戦略的SWOT分析
    RSWM Ltd. (RSWM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • PT Apexindo Pratama Duta Tbk (APEX):企業の財務・戦略的SWOT分析
    PT Apexindo Pratama Duta Tbk (APEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • S. Kumars Nationwide Ltd:企業の戦略・SWOT・財務情報
    S. Kumars Nationwide Ltd - Strategy, SWOT and Corporate Finance Report Summary S. Kumars Nationwide Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • OraSure Technologies Inc (OSUR):企業の財務・戦略的SWOT分析
    OraSure Technologies Inc (OSUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Akari Therapeutics Plc (AKTX):企業の財務・戦略的SWOT分析
    Summary Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company that develops treatments for rare and orphan autoimmune and inflammatory diseases. The company offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a …
  • Denbury Resources Inc.:企業の戦略・SWOT・財務情報
    Denbury Resources Inc. - Strategy, SWOT and Corporate Finance Report Summary Denbury Resources Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Catalent Inc:企業の戦略・SWOT・財務情報
    Catalent Inc - Strategy, SWOT and Corporate Finance Report Summary Catalent Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • UnionBank of the Philippines (UBP):企業の財務・戦略的SWOT分析
    UnionBank of the Philippines (UBP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Oramed Pharmaceuticals Inc (ORMP):製薬・医療:M&Aディール及び事業提携情報
    Summary Oramed Pharmaceuticals Inc (Oramed) engages in the research and development of novel pharmaceutical solutions, comprising an oral insulin capsule for the treatment of individuals with diabetes, and orally ingestible capsules or pills for delivery of other polypeptides. It developed a unique …
  • A&E Medical Corp:医療機器:M&Aディール及び事業提携情報
    Summary A&E Medical Corp (A&E Medical), a subsidiary of Vance Street Capital LLC, is a medical device company that manufactures and distributes surgical equipment. The company offers products such as temporary cardiac pacing wires, sternotomy sutures, lluminated vein harvest retractors, electrosurgi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆